Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

Article  PubMed  Google Scholar 

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.

Article  CAS  PubMed  Google Scholar 

Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou S-HI, Pacheco JM, et al. Adagrasib in Non-small-cell Lung Cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387:120–31.

Article  PubMed  Google Scholar 

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus Crizotinib in untreated ALK-Positive non-small-cell Lung Cancer. N Engl J Med. 2017;377:829–38.

Article  CAS  PubMed  Google Scholar 

Wolf J, Seto T, Han J-Y, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-Mutated or MET-Amplified non-small-cell Lung Cancer. N Engl J Med. 2020;383:944–57.

Article  CAS  PubMed  Google Scholar 

Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963–71.

Article  PubMed  PubMed Central  Google Scholar 

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, et al. Dabrafenib plus Trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307–16.

Article  CAS  PubMed  Google Scholar 

Drilon A, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD, et al. Efficacy and safety of Larotrectinib in patients with tropomyosin receptor kinase Fusion-positive lung cancers. JCO Precis Oncol. 2022;6:e2100418.

Article  PubMed  PubMed Central  Google Scholar 

Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, et al. Efficacy of Selpercatinib in RET Fusion-positive non-small-cell Lung Cancer. N Engl J Med. 2020;383:813–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21:271–82.

Article  CAS  PubMed  Google Scholar 

Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21:261–70.

Article  CAS  PubMed  Google Scholar 

Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-Mutated Advanced Non-small-cell Lung Cancer. N Engl J Med. 2018;378:113–25.

Article  CAS  PubMed  Google Scholar 

Gainor JF, Curigliano G, Kim D-W, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22:959–69.

Article  CAS  PubMed  Google Scholar 

Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in Non-small-cell Lung Cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383:931–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33:1974–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, et al. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021;11:838–57.

Article  CAS  PubMed  Google Scholar 

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-small-cell Lung Cancer. N Engl J Med. 2015;373:1627–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced squamous-cell non-small-cell Lung Cancer. N Engl J Med. 2015;373:123–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive non-small-cell Lung Cancer. N Engl J Med. 2016;375:1823–33.

Article  CAS  PubMed  Google Scholar 

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus Docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–65.

Article  PubMed  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-small-cell Lung Cancer. N Engl J Med. 2017;377:1919–29.

Article  CAS  PubMed  Google Scholar 

Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592–604.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Ciuleanu T-E, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198–211.

Article  CAS  PubMed  Google Scholar 

Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus Docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.

Article  CAS  PubMed  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-small-cell Lung Cancer. N Engl J Med. 2018;378:2078–92.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus Chemotherapy for squamous non-small-cell Lung Cancer. N Engl J Med. 2018;379:2040–51.

Article  CAS  PubMed  Google Scholar 

Gt G, Lm W, Mb A. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. The Lancet Oncology [Internet]. 2016 [cited 2023 Mar 12];17. Available from: https://pubmed.ncbi.nlm.nih.gov/27924752/.

Lm S. Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc [Internet]. 2022 [cited 2023 Mar 12];35. Available from: https://pubmed.ncbi.nlm.nih.gov/34608245/.

Sp P. R K. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular cancer therapeutics [Internet]. 2015 [cited 2023 Mar 12];14. Available from: https://pubmed.ncbi.nlm.nih.gov/25695955/.

Sabbatino F, Liguori L, Polcaro G, Salvato I, Caramori G, Salzano FA, et al. Role of human leukocyte Antigen System as a predictive biomarker for checkpoint-based immunotherapy in Cancer patients. Int J Mol Sci. 2020;21:7295.

Article  CAS  PubMed  PubMed Central  Google Scholar 

H, U. M M-K. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond. Virchows Archiv: an international journal of pathology [Internet]. 2021 [cited 2023 Mar 12];478. Available from: https://pubmed.ncbi.nlm.nih.gov/33486574/.

O’Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23:1274–86.

Article  PubMed  Google Scholar 

de With M, Hurkmans DP, Oomen-de Hoop E, Lalouti A, Bins S, El Bouazzaoui S, et al. Germline variation in PDCD1 is Associated with overall survival in patients with metastatic melanoma treated with Anti-PD-1 monotherapy. Cancers (Basel). 2021;13:1370.

Article  PubMed  Google Scholar 

Kula A, Dawidowicz M, Kiczmer P, Prawdzic Seńkowska A, Świętochowska E. The role of genetic polymorphism within PD-L1 gene in cancer. Rev Exp Mol Pathol. 2020;116:104494.

Article  CAS  Google Scholar 

Kobayashi M, Numakura K, Hatakeyama S, Muto Y, Sekine Y, Sasagawa H, et al. Severe Immune-related adverse events in patients treated with Nivolumab for metastatic renal cell Carcinoma are Associated with PDCD1 polymorphism. Genes (Basel). 2022;13:1204.

Article  CAS  PubMed  Google Scholar 

Deplancke B, Alpern D, Gardeux V. The Genetics of transcription factor DNA binding variation. Cell. 2016;166:538–54.

Article  CAS  PubMed  Google Scholar 

Abramov S, Boytsov A, Bykova D, Penzar DD, Yevshin I, Kolmykov SK, et al. Landscape of allele-specific transcription factor binding in the human genome. Nat Commun. 2021;12:2751.